The purpose of this legislation is to improve healthcare coverage for individuals suffering from dialysis-related amyloidosis, a condition that can arise in patients undergoing dialysis treatment. The main objective is to ensure that specific treatments for this condition are covered under Medicare, which is the federal health insurance program primarily for people aged 65 and older, as well as for some younger individuals with disabilities. Key provisions of the legislation include the addition of coverage for treatments related to dialysis-related amyloidosis under Medicare.